{
    "title": "Celgene abandons Crohn's drug trials, shares drop",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4998754/Celgene-stop-testing-Crohns-drug-shares-drop.html",
    "date": "2017-10-19",
    "keywords": [
        "drug",
        "celgene",
        "treatment",
        "disease",
        "pipeline",
        "percent",
        "mongersen",
        "study",
        "stanley",
        "colitis",
        "bowel",
        "crohns",
        "corp",
        "setback",
        "biotechnology",
        "dependence",
        "mainstay",
        "trading",
        "analysis",
        "data",
        "monitoring",
        "committee",
        "decision",
        "lack",
        "efficacy",
        "management",
        "safety",
        "latestage",
        "extension",
        "upside",
        "driver",
        "morgan",
        "thomson",
        "midstage",
        "company",
        "charge",
        "range",
        "share",
        "tax",
        "discontinuation",
        "myleoma",
        "revlimid",
        "revenue",
        "quarter",
        "amp",
        "foundation",
        "lining",
        "tract",
        "pain",
        "diarrhoea",
        "bleeding",
        "nervousness",
        "stock",
        "sellside",
        "commentary",
        "analyst",
        "note",
        "reporting",
        "tamara",
        "banerjee",
        "bengaluru",
        "editing",
        "sriraj",
        "kalluvila"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}